CA2543650C — A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
Assigned to Eisai R&D Management Co Ltd · Expires 2010-10-26 · 16y expired
What this patent protects
Disclosed is a crystalline form of the hydrochloride or hydrobromide salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoline-carboxamide, which has excellent characteristics in terms of physical properties and pharmacokinetics, particularly dissolution…
USPTO Abstract
Disclosed is a crystalline form of the hydrochloride or hydrobromide salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoline-carboxamide, which has excellent characteristics in terms of physical properties and pharmacokinetics, particularly dissolution rate and bioavailability, and thus is useful as an angiogenesis inhibitor or c-Kit kinase inhibitor.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.